Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies

NCT06906380 is registered in ClinicalTrials.gov with ARCE Therapeutics, Inc. as lead sponsor.

NCT NCT06906380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies
Lead sponsor
ARCE Therapeutics, Inc.
Phase
Observational
Overall status
Not yet recruiting
Start date
March 15, 2026
Completion date
October 31, 2040
Enrollment
49 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, acute myeloid leukemia, in relapsed or refractory, mds (myelodysplastic syndrome)